Bioactivity and prostate tissue distribution of metformin in a preprostatectomy prostate cancer cohort.

ABSTRACT: Metformin has recently been shown to have potential to reduce prostate cancer risk. We conducted a randomized, double-blind, placebo-controlled trial to determine the modulating effects of metformin on tissue and systemic biomarkers of drug activity and its distribution into the prostate tissue. Twenty patients with prostate cancer scheduled to undergo prostatectomy were randomly assigned to receive either extended-release metformin or placebo for a median of 34 days before surgery. Prostatectomy and serum samples were analyzed for metformin concentrations, serum biomarkers of drug activity (prostate-specific antigen, insulin, insulin-like growth factor-1, insulin-like growth factor binding protein 3, sex hormone-binding globulin, and testosterone) and tissue biomarkers of proliferation, a

SUBMITTER: Nguyen MM 

PROVIDER: S-EPMC5756696 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature